The stock of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has increased by 3.30 when compared to last closing price of 15.75. Despite this, the company has experienced a -3.78% fall in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-27 that Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
Is It Worth Investing in Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Right Now?
The price-to-earnings ratio for Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) is above average at 26.71x. The 36-month beta value for CPRX is also noteworthy at 0.89. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CPRX is 99.84M, and at present, short sellers hold a 5.83% of that float. The average trading volume of CPRX on March 28, 2024 was 1.49M shares.
CPRX’s Market Performance
CPRX’s stock has seen a -3.78% decrease for the week, with a 13.38% rise in the past month and a -5.08% fall in the past quarter. The volatility ratio for the week is 4.08%, and the volatility levels for the past 30 days are at 4.40% for Catalyst Pharmaceuticals Inc The simple moving average for the past 20 days is 0.48% for CPRX’s stock, with a 17.01% simple moving average for the past 200 days.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Citigroup repeating the rating for CPRX by listing it as a “Buy.” The predicted price for CPRX in the upcoming period, according to Citigroup is $27 based on the research report published on March 14, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $23. The rating they have provided for CPRX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to CPRX, setting the target price at $30 in the report published on December 21st of the previous year.
CPRX Trading at 8.92% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.70% of loss for the given period.
Volatility was left at 4.40%, however, over the last 30 days, the volatility rate increased by 4.08%, as shares surge +11.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.30% upper at present.
During the last 5 trading sessions, CPRX fell by -3.78%, which changed the moving average for the period of 200-days by +40.02% in comparison to the 20-day moving average, which settled at $16.28. In addition, Catalyst Pharmaceuticals Inc saw -3.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Harper Molly, who sale 14,000 shares at the price of $14.39 back on Dec 15 ’23. After this action, Harper Molly now owns 0 shares of Catalyst Pharmaceuticals Inc, valued at $201,420 using the latest closing price.
Tierney David S, the Director of Catalyst Pharmaceuticals Inc, sale 50,000 shares at $13.32 during a trade that took place back on Dec 12 ’23, which means that Tierney David S is holding 333,541 shares at $666,250 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.85 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.18. The total capital return value is set at 0.22. Equity return is now at value 20.75, with 16.82 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 40.37.
Currently, EBITDA for the company is 119.95 million with net debt to EBITDA at -1.12. When we switch over and look at the enterprise to sales, we see a ratio of 4.48. The receivables turnover for the company is 7.44for trailing twelve months and the total asset turnover is 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In summary, Catalyst Pharmaceuticals Inc (CPRX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
